Epidemiology
Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency, often simply called ENPP1 deficiency, is an extremely rare genetic disease. Recent research has helped scientists better understand just how many people might be affected by this condition, though the actual number of diagnosed patients remains quite small worldwide.[4]
Early estimates suggested that approximately one in every 200,000 pregnancies might be affected by ENPP1 deficiency. However, more recent and comprehensive studies using larger genetic databases have painted a different picture. By examining the genetic information of approximately 140,000 individuals and using improved methods to interpret genetic variants, researchers now estimate that the genetic prevalence is approximately one in every 64,000 pregnancies. This means the condition is more than three times more common than initially thought, suggesting that many patients with ENPP1 deficiency remain undiagnosed around the world.[4]
The frequency of people who carry one copy of an ENPP1 gene variant—known as carriers—appears to vary across different populations. Research indicates that carrier frequency is highest in East Asian populations, though this finding is based on a relatively small sample size and needs further confirmation. These geographic differences highlight the need for expanded genetic testing efforts, particularly in non-European populations where awareness of the disease may be lower and diagnostic resources may be less available.[4]
The true burden of ENPP1 deficiency on healthcare systems and affected families is likely underestimated due to several factors. The disease presents with a wide range of symptoms that can vary significantly from person to person, even within the same family. This variability, combined with low clinical awareness among healthcare providers and the complexity of diagnosis, means many cases may go unrecognized or be misdiagnosed as other conditions.[4]
Causes
ENPP1 deficiency is caused by changes, or mutations, in the ENPP1 gene. This gene provides the instructions for making a protein called ectonucleotide pyrophosphatase/phosphodiesterase 1, which is simply referred to as the ENPP1 protein. For a person to develop ENPP1 deficiency, they must inherit two faulty copies of this gene—one from each parent. This pattern of inheritance is called autosomal recessive, meaning both copies of the gene must be altered for the disease to manifest.[1][2]
When someone inherits two mutated ENPP1 genes (either two identical mutations or two different mutations), their body cannot produce enough functional ENPP1 protein. In some cases, the protein may be completely absent. Without adequate ENPP1 protein activity, the body loses its ability to properly regulate certain critical processes related to calcium deposits and bone formation.[17]
The ENPP1 protein normally works on the surface of cells where it breaks down a molecule called adenosine triphosphate, or ATP. When ATP is broken down by ENPP1, it creates two important substances: adenosine monophosphate (AMP) and pyrophosphate (PPi). Pyrophosphate plays a vital role in preventing calcium and other minerals from building up in the wrong places in the body, particularly in soft tissues like blood vessels. At the same time, pyrophosphate helps ensure that bones mineralize properly.[1][2]
Parents who each carry one mutated copy of the ENPP1 gene are called carriers. Carriers typically do not show symptoms of the disease because they have one working copy of the gene, which produces enough ENPP1 protein for normal function. However, when two carriers have children together, there is a 25% chance with each pregnancy that their child will inherit both mutated copies and develop ENPP1 deficiency.[2]
More than 40 different mutations in the ENPP1 gene have been identified in patients with this condition. These mutations can affect different parts of the gene and the protein it produces, which may explain why the disease can present so differently from one patient to another. Some mutations severely impair the protein’s ability to break down ATP and produce pyrophosphate, while others may affect different functions of the protein.[2][3]
Risk Factors
The primary risk factor for developing ENPP1 deficiency is having parents who are both carriers of mutations in the ENPP1 gene. Because this is an autosomal recessive genetic condition, a child must inherit one mutated gene from each parent to develop the disease. Families with a history of ENPP1 deficiency or related conditions face a higher risk with each pregnancy.[2]
Populations where carrier frequency is higher naturally face increased risk of the disease appearing in newborns. Studies suggest that East Asian populations may have higher carrier frequencies for ENPP1 variants, though more research is needed to confirm this finding across larger population samples. In communities where marriages between related individuals are more common, the risk of two carriers having children together increases.[4]
Parents who are known carriers—perhaps identified through genetic testing during pregnancy planning or after having an affected child—face a 25% chance with each pregnancy of having another child with ENPP1 deficiency. This risk remains constant with each pregnancy, regardless of how many unaffected children they may have had previously.[2]
Limited access to genetic testing and specialized medical care in certain geographic regions or socioeconomic groups may delay diagnosis, though this does not affect the actual occurrence of the disease. Low awareness among healthcare providers about ENPP1 deficiency can also lead to missed or delayed diagnoses, potentially affecting outcomes even though it doesn’t change who develops the condition.[4]
Symptoms
The symptoms of ENPP1 deficiency vary dramatically depending on the age at which the disease manifests and its severity. The condition presents as a spectrum of disorders that can affect infants, children, and adults in distinctly different ways, though some individuals experience complications throughout their entire lives.[1][3]
When ENPP1 deficiency presents before birth or in early infancy, it is typically diagnosed as generalized arterial calcification of infancy, abbreviated as GACI. Babies with this severe form develop extensive calcium deposits in the walls of their blood vessels, particularly in medium and large arteries. The blood vessel walls become stiff and hardened, and the vessels may narrow due to abnormal growth of cells in the vessel lining, a process called neointimal proliferation. These changes drastically reduce blood flow, preventing oxygen-rich blood from reaching vital organs.[1][14]
Infants with GACI may show signs of heart failure, struggle to breathe, have extremely high blood pressure, fail to gain weight properly, appear blue due to poor oxygen circulation, or experience swelling in their bodies. The heart must work much harder to pump blood through stiffened, narrowed vessels, which can lead to an enlarged heart. In the most tragic cases, these babies may suffer heart attacks, strokes, or failure of multiple organs. The prognosis for infants with GACI is extremely poor—approximately 45 to 50 percent of these babies die within the first six months of life despite receiving supportive medical care.[1][10][14]
Children who survive the infant stage or who never experienced severe cardiovascular problems in infancy typically develop a condition called autosomal recessive hypophosphatemic rickets type 2, or ARHR2. In this form of the disease, children have low levels of phosphate in their blood, which severely affects bone development. These children develop rickets—a condition where bones become soft, weak, and deformed. They may have bowed legs, impaired growth leading to short stature, curved bones, and difficulty walking normally. The pain in their bones can be significant and limit their ability to play and move like other children their age.[1][10]
Children with ARHR2 may also develop hearing loss, which can affect their ability to communicate and learn. Some continue to have high blood pressure that began in infancy, and calcium deposits may form around their joints, particularly in the knees, hips, ankles, hands, and neck. These deposits can cause joint stiffness and pain that interferes with normal childhood activities.[1][17]
As people with ENPP1 deficiency reach adulthood, they often continue to experience progressive complications. Adults may suffer from osteomalacia, which is the adult form of rickets where bones become increasingly soft and prone to fractures. This bone softening causes persistent pain that can severely impact quality of life and independence. Many adults cannot work or engage in normal daily activities due to pain and limited mobility.[1][17]
Adults with ENPP1 deficiency frequently experience painful, stiff joints due to calcium deposits forming in and around the joints and in the ligaments and tendons that connect muscles to bones—a condition called enthesopathy. These calcifications commonly affect the knees, hips, spine, hands, and ankles, making movement difficult or impossible. Some adults develop abnormal curvature or fusion of spinal bones. Hearing loss may worsen over time, and some adults continue to have heart valve problems or persistent high blood pressure.[14][17]
Prevention
Because ENPP1 deficiency is an inherited genetic condition caused by mutations passed from parents to children, there is no way to prevent the disease from occurring once a child inherits two mutated copies of the ENPP1 gene. However, families with a history of the condition or known carriers can take steps to make informed reproductive decisions.[2]
For couples who are both known carriers of ENPP1 mutations, genetic counseling before pregnancy can provide valuable information about their risk of having an affected child. Genetic counselors can explain the 25% chance with each pregnancy of having a child with ENPP1 deficiency, discuss available testing options during pregnancy, and help families understand what these results mean for family planning decisions.[4]
Prenatal genetic testing can identify whether a developing fetus has inherited two mutated ENPP1 genes. This testing allows families to prepare for the specialized medical care their baby will need immediately after birth, or to make personal decisions about continuing or ending the pregnancy based on their values and circumstances. Early identification before birth can ensure that appropriate medical teams are ready to provide immediate intervention, which may improve outcomes in some cases.[4]
Expanded genetic screening programs, particularly in populations where carrier frequency is higher, could identify carriers before they have children. This knowledge would allow carriers to make informed decisions about genetic testing with partners and pregnancy planning. However, such population-wide screening programs are not currently widely available for ENPP1 deficiency.[4]
Increasing awareness among healthcare providers about ENPP1 deficiency can lead to earlier diagnosis and treatment, which may prevent some of the progressive complications even though it cannot prevent the underlying disease. When doctors recognize the early signs of GACI in newborns or rickets in children, prompt genetic testing and confirmation allows families to access specialized care, participate in clinical trials if eligible, and connect with patient support organizations.[4][16]
For families who already have one child with ENPP1 deficiency, genetic testing of the parents to confirm carrier status and understanding the recurrence risk helps them make informed decisions about future pregnancies. Some families may choose to pursue options like in vitro fertilization with genetic testing of embryos before implantation, though these options may not be accessible or acceptable to all families.[2]
Pathophysiology
The pathophysiology of ENPP1 deficiency—meaning how the disease causes changes in normal body function—centers on the disruption of a critical biochemical pathway that controls where and how calcium and other minerals are deposited in the body. Understanding these processes helps explain why the disease causes such seemingly contradictory problems: too much calcium in soft tissues like blood vessels while having too little proper bone formation.[11][19]
The ENPP1 protein normally sits on the outer surface of cells where it performs an essential job. It breaks down adenosine triphosphate (ATP)—a molecule cells release into the space around them—into two products: adenosine monophosphate (AMP) and inorganic pyrophosphate (PPi). This reaction is not just about breaking down ATP; both products play crucial roles in regulating body processes. ENPP1 represents the main source of pyrophosphate in the blood and tissues.[1][14]
Pyrophosphate acts as a powerful brake on calcium mineralization. It prevents the formation and growth of hydroxyapatite crystals, which are the mineral crystals that should form in bones but should not form in soft tissues. Under normal circumstances, pyrophosphate circulates through blood vessels and bathes soft tissues, continuously preventing inappropriate calcium deposits. In bones, however, controlled hydroxyapatite formation is necessary for proper bone strength and structure.[1][11]
When ENPP1 protein is deficient or absent, the body cannot produce enough pyrophosphate. With this critical brake removed, hydroxyapatite crystals begin forming in places they should never be—particularly in the elastic layers of artery walls. These crystals accumulate over time, causing blood vessels to stiffen and lose their flexibility. The vessels can no longer expand and contract normally with each heartbeat, which increases blood pressure and forces the heart to work harder.[14][19]
The calcification in blood vessels is not the only problem. ENPP1 deficiency also triggers abnormal growth of cells in the inner lining of blood vessels, creating a thickened layer that narrows the vessel opening. This neointimal proliferation further restricts blood flow, compounding the problems caused by vessel stiffening. The reduced blood flow means organs receive less oxygen, which can lead to organ damage and failure.[1][14]
At the same time, bones fail to mineralize properly in ENPP1 deficiency, though the exact mechanisms are complex and not fully understood. The disease causes increased levels of a hormone called FGF23 (fibroblast growth factor 23), which tells the kidneys to excrete more phosphate in urine. This leads to low blood phosphate levels, a condition called hypophosphatemia. Phosphate is essential for bone formation, so its deficiency results in soft, weak bones that bow under body weight and break easily.[14][19]
The paradox of ENPP1 deficiency—simultaneous over-mineralization of soft tissues and under-mineralization of bones—reflects the disruption of the body’s delicate mineral balance. The same pathway that should prevent calcium deposits in arteries should also ensure adequate calcium and phosphate deposition in bones. When ENPP1 is absent, both processes go wrong in opposite directions. Scientists describe this phenomenon as “paradoxical mineralization” because it seems contradictory but actually represents two sides of the same underlying metabolic disruption.[11][19]
The ENPP1 protein also produces adenosine as a byproduct of its activity. Low adenosine levels in ENPP1 deficiency may contribute to the blood vessel problems, as adenosine normally helps regulate vessel health and prevents excessive cell growth. This means the disease affects not just calcium balance but multiple signaling pathways that maintain cardiovascular health.[7][11]
The progressive nature of ENPP1 deficiency reflects the ongoing accumulation of calcium deposits in inappropriate locations and the continued failure of bones to mineralize properly. Without treatment, these processes continue throughout life, explaining why symptoms often worsen with age and why new complications can emerge even in adults who survived the dangerous infant period.[3][21]
